A Phase 2 interventional study of Pembrolizumab in Squamous Cell Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 59 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pembrolizumab in Carcinoma, Squamous Cell — 3 open to participants now, 7 under way, none of them phase 3. pembrolizumab · Carcinoma, Squamous Cell.
Among the 17 studies testing pembrolizumab in Carcinoma, Squamous Cell, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 13 in phase 2, and was the 7th registered.
628 studies on the registry are indexed under Carcinoma, Squamous Cell; 134 are open to participants now.
Browse Carcinoma, Squamous Cell studies →3 of the 17 studies testing pembrolizumab in Carcinoma, Squamous Cell are open now, in 1 country. Recruiting first, the newest first:
Diwakar Davar · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
17 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 45 across 477 interventional studies indexed under Carcinoma, Squamous Cell.
Median enrollment 48 across the 17 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,166 studies on the registry; 131 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 8 studies filed under Carcinoma, Squamous Cell — fewer than ten, so there is no comparison to draw.
1 of the studies testing pembrolizumab in Carcinoma, Squamous Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05366166UNC Lineberger Comprehensive Cancer CenterPembrolizumab Plus Olaparib in LA-HNSCC | 2027-01-21 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing pembrolizumab in Carcinoma, Squamous Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(Notes: Participants must have recovered from all AEs due to previously administered therapies to ≤ Grade 1 or baseline. If a participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
Biological: Pembrolizumab
Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
Biological: Pembrolizumab
IV infusion
Also known as: KEYTRUDA®, MK-3475
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who have best response of Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). ORR per RECIST 1.1 as assessed by blinded independent central review (BICR) is presented.
Time frame: Up to approximately 32 months
Duration of Response (DOR)
For participants who demonstrated a confirmed CR or PR per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. The DOR per RECIST 1.1 as assessed by BICR is presented for all participants who experienced a confirmed CR or PR.
Time frame: Up to approximately 56 months
Disease Control Rate (DCR)
DCR is defined as the percentage of participants who have a CR or PR or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease). The DCR per RECIST 1.1 as assessed by BICR is presented.
Time frame: Up to approximately 56 months
Progression-free Survival (PFS)
PFS was defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurred first. PFS per RECIST 1.1 as assessed by BICR is presented.
Time frame: Up to approximately 56 months
Overall Survival (OS)
OS was defined as the time from first dose of study treatment to death due to any cause. The OS for all participants is presented.
Time frame: Up to approximately 56 months
Number of Participants Who Experienced One or More Adverse Events (AEs)
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy. The number of participants who experienced an AE is presented.
Time frame: Up to approximately 56 months
Number of Participants Who Discontinued Study Treatment Due to AE
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy. The number of participants who discontinued study treatment due to an AE is presented.
Time frame: Up to approximately 56 months
| Milestone | Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Started | 105 | 54 |
| Participants that received a second course of pembrolizumab | 2 | 1 |
| Completed | 0 | 0 |
| Not completed | 105 | 54 |
| Withdrew: Death | 70 | 24 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Sponsor's decision | 27 | 22 |
ORR was defined as the percentage of participants who have best response of Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). ORR per RECIST 1.1 as assessed by blinded independent central review (BICR) is presented.
| Percentage of participants | Recurrent or Metastatic Cutaneous cSCC Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Objective Response Rate (ORR) | 35.2 (26.2 to 45.2) | 51.9 (37.8 to 65.7) |
For participants who demonstrated a confirmed CR or PR per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. The DOR per RECIST 1.1 as assessed by BICR is presented for all participants who experienced a confirmed CR or PR.
| Months | Recurrent or Metastatic Cutaneous cSCC Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Duration of Response (DOR) | 1.6 (1.2 to 24.7) | 2.7 (1.1 to 12.3) |
DCR is defined as the percentage of participants who have a CR or PR or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease). The DCR per RECIST 1.1 as assessed by BICR is presented.
| Percentage of participants | Recurrent or Metastatic Cutaneous cSCC Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Disease Control Rate (DCR) | 52.4 (42.4 to 62.2) | 64.8 (50.6 to 77.3) |
PFS was defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurred first. PFS per RECIST 1.1 as assessed by BICR is presented.
| Months | Recurrent or Metastatic Cutaneous cSCC Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Progression-free Survival (PFS) | 5.7 (3.1 to 8.5) | 14.4 (5.5 to 43.6) |
OS was defined as the time from first dose of study treatment to death due to any cause. The OS for all participants is presented.
| Months | Recurrent or Metastatic Cutaneous cSCC Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Overall Survival (OS) | 23.8 (13.4 to 30.9) | NA (33.3 to NA) |
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy. The number of participants who experienced an AE is presented.
| Participants | Recurrent or Metastatic Cutaneous cSCC Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Number of Participants Who Experienced One or More Adverse Events (AEs) | 102 | 51 |
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy. The number of participants who discontinued study treatment due to an AE is presented.
| Participants | Recurrent or Metastatic Cutaneous cSCC Cohort | Locally Advanced Unresectable cSCC Cohort |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to AE | 20 | 11 |
Collected over Up to approximately 56 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course | 97/159 (61%) | 87/159 (54.7%) | 139/159 (87.4%) |
| Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course | 1/3 (33.3%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Event | Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course | Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course |
|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 0/159 | 1/3 |
| Scrotal cellulitisInfections and infestations | 0/159 | 1/3 |
| SepsisInfections and infestations | 4/159 | 1/3 |
| Weight decreasedInvestigations | 0/159 | 1/3 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/159 | 1/3 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/159 | 0/3 |
| PneumoniaInfections and infestations | 5/159 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 3/159 | 0/3 |
| Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/159 | 0/3 |
| Acute myocardial infarctionCardiac disorders | 2/159 | 0/3 |
| Event | Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC First Course | Recurrent or Metastatic Cutaneous and Locally Advanced Unresectable cSCC Second Course |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 31/159 | 1/3 |
| AstheniaGeneral disorders | 35/159 | 1/3 |
| Blood bilirubin increasedInvestigations | 3/159 | 1/3 |
| Blood phosphorus decreasedInvestigations | 2/159 | 1/3 |
| Blood urea increasedInvestigations | 2/159 | 1/3 |
| Protein total decreasedInvestigations | 1/159 | 1/3 |
| HyperchloraemiaMetabolism and nutrition disorders | 1/159 | 1/3 |
| HypocalcaemiaMetabolism and nutrition disorders | 4/159 | 1/3 |
| HyponatraemiaMetabolism and nutrition disorders | 4/159 | 1/3 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/159 | 1/3 |
The analysis population consisted of all participants who received ≥1 dose of study treatment.
| Age, Continuous(Years) | Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort | Locally Advanced Unresectable cSCC Cohort | Total |
|---|---|---|---|
| Mean | 70.0 ± 14.3 | 73.7 ± 12.4 | 71.3 ± 13.8 |
| Sex: Female, Male(Participants) | Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort | Locally Advanced Unresectable cSCC Cohort | Total |
|---|---|---|---|
| Female | 25 | 15 | 40 |
| Male | 80 | 39 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort | Locally Advanced Unresectable cSCC Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 2 | 15 |
| Not Hispanic or Latino | 57 | 40 | 97 |
| Unknown or Not Reported | 35 | 12 | 47 |
| Race (NIH/OMB)(Participants) | Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort | Locally Advanced Unresectable cSCC Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 68 | 40 | 108 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 32 | 12 | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2017 to primary completion in Jul 2020, 33 months.
Results were first posted in Nov 2021, 1 year 3 months after primary completion. A results delay was requested in Jul 2021.
Of 98 phase 2 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 82. This study's 33 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab